Boston Scientific

Health Care Health Care Equipment Marlborough, Massachusetts Last filing Feb 17, 2026 · FY2025

                    Revenue
                    FY2025
                
$20.1B
                    3y CAGR +16.5%
                    
                    P93
                    
                    n/a
                    
                    Net income
                    FY2025
                
$2.9B
                    Net margin +14.4%
                    
                    P62
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$43.7B
                    ROA +6.6%
                    
                    P58
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$4.5B
                    FCF margin +18.2%
                    
                    P65
                    
                    n/a

19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

31 accounts · 1 year

Total assets $43.7B

Total liabilities $5.4B

Shareholders equity $24.2B

Account	2025	Trend
Assets
Cash and Cash Equivalents	4.5%
Short Term Investments	0.0%
Accounts Receivable	7.0%
Inventory	6.7%
Prepaid Expenses	1.5%
Total Current Assets	20.1%
Property,Plant and Equipment	9.2%
Operating Lease Assets	1.1%
Goodwill	41.9%
Intangible Assets	16.1%
Long Term Investments	0.9%
Deferred Tax Assets	8.4%
Other Noncurrent Assets	4.3%
Total Assets	100.0%
Liabilities
Accounts Payable	2.6%
Accrued Liabilities	7.3%
Current Portion of Long Term Debt	0.7%
Other Current Liabilities	1.8%
Total Current Liabilities	12.5%
Deferred Tax Liabilities	0.5%
Other Noncurrent Liabilities	5.5%
Total Liabilities	12.5%
Equity
Preferred Stock	0.0%
Common Stock	0.0%
Additional Paid In Capital	49.2%
Retained Earnings	12.8%
Treasury Stock	5.2%
Accumulated Other Comprehensive Income	-1.4%
Noncontrolling Interest	0.5%
Total Stockholders Equity	55.5%
Total Liabilitiesand Equity	100.0%

Income Statement

Revenue, expense, and profitability

20 accounts · 1 year

Revenue $20.1B

Operating income $3.6B

Net income $2.9B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	46.0%
Expenses Cost of Revenue	14.2%
Expenses Research and Development	4.7%
Expenses Selling,General and Administrative	15.8%
Expenses Depreciation and Amortization	3.1%
Expenses Share Based Compensation	0.7%
Expenses Restructuring and Asset Impairment	0.2%
Expenses Operating Expenses	23.4%
Other Income Expense Gross Profit	31.7%
Other Income Expense Operating Income	8.3%
Other Income Expense Interest Expense	0.8%
Other Income Expense Other Income/expense	-0.5%
Other Income Expense Income Before Tax	7.8%
Income Tax Income Tax Expense	1.1%
net Income net Income	6.6%
net Income Comprehensive Income	4.6%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	3.4%
Earnings Per Share Weighted Average Shares Diluted	3.4%

Cash Flow Statement

Operating, investing, and financing flows

19 accounts · 1 year

Operating cash flow $4.5B

Investing cash flow $-2.6B

Financing cash flow $-395.0M

Account	2025	Trend
CashFlow
Operating Activities net Income	6.6%
Operating Activities Depreciation and Amortization	1.1%
Operating Activities Stock Based Compensation	0.7%
Operating Activities Deferred Income Taxes	-0.0%
Operating Activities Changes In Operating Assets and Liabilities	1.0%
Operating Activities Other Non Cash Items	0.1%
Operating Activities net Cash From Operating Activities	10.4%
Investing Activities Capital Expenditures	2.0%
Investing Activities Business Acquisitions	3.6%
Investing Activities Other Investing Activities	-0.2%
Investing Activities net Cash From Investing Activities	-6.0%
Financing Activities Proceeds From Debt	3.6%
Financing Activities Proceeds From Stock Issuance	0.6%
Financing Activities Other Financing Activities	0.0%
Financing Activities net Cash From Financing Activities	-0.9%
Cash Reconciliation Effect of Exchange Rate On Cash	0.1%
Cash Reconciliation net Change In Cash	3.5%
Cash Reconciliation Cash At Beginning of Period	4.9%
Cash Reconciliation Cash At End of Period	4.9%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+69.0%
Operating margin	+18.0%
Net margin	+14.4%
FCF margin	+18.2%
Growth
Revenue CAGR (3y)	+16.5%
Returns
ROE	+11.9%
ROA	+6.6%
ROIC	+13.7%
Liquidity
Current ratio	1.62x
Quick ratio	0.92x
Leverage
D/E	0.22x
Interest coverage	10.35x
Efficiency
Asset turnover	0.46x
Cash conversion cycle	+161d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Boston Scientific

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history